Project Grant R21AI193387
Award Date
7/18/25
Completion Date
6/30/27
Dollars Obligated
$405K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $200,016 to The Regents of the University of California, San Francisco (UCSF) to develop a non-viral genome editing therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). The 5-year project aims to establish expertise in non-viral CRISPR/Cas9 editing of human hematopoietic stem cells, preclinical...
This federal Project Grant award of $1,638,033, provided by the National Institutes of Health (NIH) under the Biomedical Research and Research Training Program (CFDA 93.859), supports the development of a CRISPR-free mammalian recombineering system at the Scripps Research Institute. The project aims to characterize and optimize a bacterial recombinase system for efficiently conducting large-scale DNA insertions, deletions, and substitutions in mammalian cells without inducing cytotoxic...
This Project Grant award, valued at $735,078, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The funding supports a 5-year research project to investigate the molecular mechanisms of innate immune memory in humans, with a focus on understanding the epigenetic determinants that enable long-lasting "trained immunity" in myeloid and lymphoid progenitor cells. The...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $192,788 to the University of California, San Diego to conduct a genome-wide screening and analysis of regulators of plasmacytoid dendritic cell (pDC) function and exhaustion. The research aims to gain a comprehensive understanding of the mechanisms that control interferon-I production and exhaustion in pDCs, which are critical innate immune...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to improve the efficiency of CRISPR gene editing in human pluripotent stem cells. The goal is to develop a novel carbon nanotube array technology that can efficiently transfer nucleic acids and proteins into these cells to enhance CRISPR-based gene editing and homology-directed recombination. The $275,045 award to Advanced Gene...
This federal Project Grant award, with ID R21AI187731, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $245,895 award, granted on November 14, 2024, supports research at the Icahn School of Medicine at Mount Sinai to systematically assess the impact of ubiquitination on Flavivirus infection using CRISPR-Cas9 base editing approaches. The goal is to discover novel pathways that promote...
This Project Grant award, valued at $792,687.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the structural features of sialoglycans necessary for influenza A virus (IAV) infection and adaptation across various host species. The key activities under this award include: 1) using CRISPR/Cas9 techniques to truncate different types of sialoglycans in human lung...
This Project Grant award, valued at $219,792.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The award, with a performance period from March 2025 to February 2027, supports the development of statistical methods to analyze high-throughput T-cell receptor sequencing (TCR-seq) data. The key objectives are to ensure that functional TCRs are not lost during data...
This Project Grant award for $862,440.00 was made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development and evaluation of a new humanized mouse model to study gene editing therapies targeting chronic hepatitis B virus (HBV) infection. The key objectives are to: 1) Evaluate the anti-HBV efficacy of HBV gene therapy in liver-humanized NSG-PIZ mice, including assessing...
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...